Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Ian J. S. Fairlamb Clear advanced filters

  • Although mechanistic understanding can drive new reactivity development, the key bond-forming and -breaking steps in catalytic cycles are often sufficiently fast to elude observation. Here, the authors photochemically produce a key intermediate in Mn-catalysed C–H functionalization, and follow the subsequent steps—spanning processes occurring over seven orders of magnitude in time—using time-resolved infrared spectroscopy.

    • L. Anders Hammarback
    • Ian P. Clark
    • Jason M. Lynam
    Research
    Nature Catalysis
    Volume: 1, P: 830-840

  • Knowledge about the full reaction signature, such as the complete profile of products and side-products is important in accelerating discovery chemistry. Here, the authors report a methodology using high-throughput experimentation and multivariate data analysis to examine Palladium- catalyzed cross-coulpling reactions.

    • George E. Clarke
    • James D. Firth
    • Ian J. S. Fairlamb
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-15

  • The replacement of palladium with other metal catalysts in C–C bond-forming reactions is attractive in terms of costs and sustainability. Now an iron-based catalyst is successfully employed in the Suzuki cross-coupling of aryl chlorides with aryl boronic esters activated with tert-butyl lithium.

    • Benjamin J. S. Rowsell
    • Harry M. O’Brien
    • Robin B. Bedford
    ResearchOpen Access
    Nature Catalysis
    Volume: 7, P: 1186-1198

  • The description of a compound (DDD107498) with antimalarial activity against multiple life-cycle stages of Plasmodium falciparum and good pharmacokinetic and safety properties, with potential for single-dose treatment, chemoprotection and prevention of transmission.

    • Beatriz Baragaña
    • Irene Hallyburton
    • Ian H. Gilbert
    Research
    Nature
    Volume: 522, P: 315-320

  • African sleeping sickness, caused by Trypanosoma brucei species, is responsible for some 30,000 human deaths each year. Available treatments are limited by poor efficacy and safety profiles. However, a new molecular target for potential treatments has now been identified. The protein target is T. brucei N-myristoyltransferase. In further experiments, lead compounds have been discovered that inhibit this protein, kill trypanosomes in vitro and in vivo, and can cure trypanosomiasis in mice.

    • Julie A. Frearson
    • Stephen Brand
    • Paul G. Wyatt
    Research
    Nature
    Volume: 464, P: 728-732

  • Primary biliary cirrhosis is an autoimmune liver disease with poor therapeutic options. Here Cordell et al. a perform meta-analysis of European genome-wide association studies identifying six novel risk loci and a number of potential therapeutic pathways.

    • Heather J. Cordell
    • Younghun Han
    • Katherine A. Siminovitch
    ResearchOpen Access
    Nature Communications
    Volume: 6, P: 1-11

  • Trypanosomatid parasites can cause life-threatening diseases, such as human African trypanosomiasis, leishmaniasis and Chagas disease. In this Review, Gilbert and colleagues discuss the drug discovery landscape and describe some of the challenges that are involved in the development of new drugs to treat these diseases.

    • Mark C. Field
    • David Horn
    • Ian H. Gilbert
    Reviews
    Nature Reviews Microbiology
    Volume: 15, P: 217-231